Apotex Resumes Shipping to the U.S.

By Apotex, PRNE
Monday, May 9, 2011

FDA's Decision to Lift Import Alert Paves the Way for Apotex's Oral Solid Dose Products to be Available Again for US Consumers; Company Moves Forward to Restore Pipeline of Shipments to the Local Market

TORONTO, May 10, 2011 - Apotex, one of the largest generic pharmaceutical manufacturers in the
world, announced it will soon resume shipments of its oral solid dose
products to the U.S. market. The announcement comes on the heels of a Food
and Drug Administration (FDA) decision to lift its import alert at Apotex's
largest solid dose manufacturing facility supplying product to the US.

"Apotex is pleased the FDA has recognized the enhancements to our global
quality systems," stated Dr Jeremy B. Desai, Apotex' Chief Operating Officer.

Apotex will immediately resume manufacturing and shipping of our solid
dose products into the US market.

About Apotex

Apotex Inc., with 6000 employees in Canada sells to 115 countries a
portfolio of approximately 300 affordable medicines around the globe and is
the largest generic company in the country. It is the top research and
development Canadian corporation in the pharmaceutical industry with
planned expenditures of $2 billion over the next ten years.

Apotex Corp. is the US Company that markets the products of Apotex, Inc.
Through its sales and marketing headquarters in Weston, Florida and
operations center in Indianapolis, Apotex Corp. is committed to providing
safe and affordable generic medicines.


    For further information:

    Elie Betito
    Tel: +1(416)749-9300 Ext. 7366
    Cell: +1(416)558-5491
    Email: ebetito@apotex.com


will not be displayed